Induction of severe systemic lupus erythematosus by TNF blockade and response to anti–IL-6 strategy - 30/03/13
Doi : 10.1016/j.jaci.2012.09.034
Sabine Adler, MD a, Mirjam Kolev, MD a, Pierre-Alain Varisco, MD a, Manuela Tham a, Michael von Gunten, MD b, Christoph Tappeiner, MD c, Peter M. Villiger, MD a 
a Department of Rheumatology, Clinical Immunology and Allergology, University Hospital and University of Bern, Bern, Switzerland
b Institute of Pathology, University of Bern, Bern, Switzerland
c Department of Ophthalmology, University Hospital, University of Bern, Bern, Switzerland
| Disclosure of potential conflict of interest: P. M. Villiger has board memberships with Roche, Novartis, Pfizer, Merck Sharp & Dohme, Abbott, Bristol-Myers Squibb, UCB, and Grünenthal; is employed by the University of Bern; and has received grants from the Swiss National Science Foundation and Lichtensteinstiftung. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2012
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 131 - N° 4
P. 1235 - avril 2013 Retour au numéro
Article précédent
- Emergency treatment for ζ chain–associated protein of 70 kDa (ZAP70) deficiency
- Vy Hong-Diep Kim, Luis Murguia, Tal Schechter, Eyal Grunebaum, Chaim M. Roifman
- Epstein-Barr virus–independent diffuse large B-cell lymphoma in DNA ligase 4 deficiency
- Chris M. Bacon, Sarah J. Wilkinson, Gavin P. Spickett, Dawn Barge, Helen H. Lucraft, Graham Jackson, Vikki Rand, Andrew R. Gennery
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?